文献速递免疫规划慢病防控与筛查卫生政策与健康促进

美国老年人呼吸道合胞病毒疫苗接种相关的临床与经济结局

Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States.
PubMed 文献 · Vaccine · 2021-12-20

该研究用决策树经济模型评估美国≥60岁人群在一个RSV季节接种假设疫苗对比不接种的临床与经济价值。价值定价为每次接种152–299美元(支付意愿100,000美元/QALY)。

要点

  • 50%效力疫苗可使每季RSV住院减少43,700–81,500例。
  • 同情景下每季避免RSV归因死亡8,000–14,900例。

核心结论

  • 尽管流行病学文献存在变异和空白,本研究提示美国老年人接种RSV疫苗具有潜在价值。
  • 分析提供了当代人群水平RSV疾病负担估计及RSV疫苗接种经济价值驱动因素的见解。

研究设计与样本

  • 研究采用决策树框架的经济模型,比较假设疫苗与不接种在一个RSV季节内对美国≥60岁成人RSV感染结局的影响。
  • 从美国文献针对性综述中选取两个共同基础情景流行病学来源:一项捕获所有RSV感染的地标性研究和一项报告医疗就诊RSV并区分轻症与中重度的当代研究。
  • 两个基础情景分析均使用RSV住院后一年内死亡风险的近期数据。
  • 直接医疗成本和每例损失的质量调整生命年(QALY)来自文献和公开来源。
  • 模型结局包括老年人群RSV疾病负担、疫苗可避免疾病负担及第三方支付方视角下疫苗的潜在价值定价。

主要发现

  • 两个基础情景分析估计,50%效力且覆盖率与流感疫苗接种相当的疫苗每RSV季节可预防43,700–81,500例RSV住院和8,000–14,900例RSV归因死亡。
  • 在支付意愿为100,000美元/QALY时,两个共同基础情景分析的价值定价为每次接种152–299美元。
  • 敏感性分析发现,疫苗接种的经济价值对RSV发病率和住院后死亡风险增加最为敏感。

局限性

  • 原文指出流行病学文献存在变异和空白(variability and gaps in the epidemiology literature)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of lower respiratory infections and hospitalizations among older adults. We aimed to estimate the potential clinical benefits and economic value of RSV vaccination of older adults in the United States (US). METHODS: We developed an economic model using a decision-tree framework to capture outcomes associated with RSV infections in US adults aged ≥ 60 years occurring during one RSV season for a hypothetical vaccine versus no vaccine. Two co-base-case epidemiology sources were selected from a targeted review of the US literature: a landmark study capturing all RSV infections and a contemporary study reporting medically attended RSV that also distinguishes mild from moderate-to-severe disease. Both base-case analyses used recent data on mortality risk in the year after RSV hospitalizations. Direct medical costs and quality-adjusted life-years (QALYs) lost per case were obtained from the literature and publicly available sources. Model outcomes included the population-level clinical and economic RSV disease burden among older adults, potential vaccine-avoidable disease burden, and the potential value-based price of a vaccine from a third-party payer perspective. RESULTS: Our two base-case analyses estimated that a vaccine with 50% efficacy and coverage matching that of influenza vaccination would prevent 43,700-81,500 RSV hospitalizations and 8,000-14,900 RSV-attributable deaths per RSV season, resulting in 1,800-3,900 fewer QALYs lost and avoiding $557-$1,024 million. Value-based prices for the co-base-case analyses were $152-$299 per vaccination at a willingness to pay of $100,000/QALY gained. Sensitivity analyses found that the economic value of vaccination was most sensitive to RSV incidence and increased posthospitalization mortality risks. CONCLUSIONS: Despite variability and gaps in the epidemiology literature, this study highlights the potential value of RSV vaccination for older adults in the US. Our analysis provides contemporary estimates of the population-level RSV disease burden and insights into the economic value drivers for RSV vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Herring WL, Zhang Y, Shinde V, et al. Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United States. Vaccine. 2021. PMID: 34933763. doi:10.1016/j.vaccine.2021.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。